← Patent-cliff monitor small molecule BRAFTOVI ENCORAFENIB
Loss of exclusivity August 2033 latest FDA-listed patent expiry
Drug detail Brand name BRAFTOVI Active ingredient ENCORAFENIB Strength 75MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval June 2018 Marketing status RX
Listed patents Patent Expires Type 9474754 August 2033 use U-4051 9763941 November 2032 use U-2335 10258622 November 2032 use U-4051 9387208 November 2032 product 9314464 July 2031 use U-4051 9593100 August 2030 product 9850230 August 2030 use U-4051 9850229 August 2030 use U-2337 9593099 August 2030 substance 10005761 August 2030 use U-4051 RE49556 February 2030 substance, product 8541575 February 2030 substance, product 8946250 July 2029 substance, product
Regulatory exclusivity Code Expires ODE-445 October 2030 I-957 December 2027 I-928 October 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.